A recent study looked at two long-acting basal insulin analogs, degludec 100 units/mL and glargine 300 units/mL. These insulins were created for an ultralong effect but had not previously been studied in comparison with each other for efficacy. The study concluded that long-acting basal insulin analogs are similar in efficacy and side effects, with comparable glycemic control and low overall incidences of hypoglycemia, so when choosing between degludec 100 and glargine 300, cost and access should be considered. Read more